• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia.

作者信息

Gangat Naseema, Bleeker Jonathan, Lynch Douglas, Olteanu Horatiu, Letendre Louis, Tefferi Ayalew

机构信息

Division of Hematology, Mayo Clinic, Rochester, MN.

Division of Hematology and Hematopathology, Sanford Health, Sioux Falls, SD.

出版信息

Haematologica. 2022 Oct 1;107(10):2523-2526. doi: 10.3324/haematol.2022.281398.

DOI:10.3324/haematol.2022.281398
PMID:35678030
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9521224/
Abstract
摘要

相似文献

1
Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia.达雷妥尤单抗用于治疗难治性获得性特发性纯红细胞再生障碍性贫血。
Haematologica. 2022 Oct 1;107(10):2523-2526. doi: 10.3324/haematol.2022.281398.
2
Daratumumab for pure red cell aplasia post ABO incompatible allogeneic hematopoietic stem cell transplant for aplastic anemia.达雷妥尤单抗治疗再生障碍性贫血患者 ABO 不合异基因造血干细胞移植后纯红细胞再生障碍。
Blood Cells Mol Dis. 2021 May;88:102464. doi: 10.1016/j.bcmd.2020.102464. Epub 2020 Jul 2.
3
Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab.达雷妥尤单抗治疗后缓解的难治性异基因干细胞移植后纯红细胞再生障碍性贫血
Am J Hematol. 2019 Aug;94(8):E216-E219. doi: 10.1002/ajh.25515. Epub 2019 Jun 7.
4
Monoclonal Gammopathy of Anemic Significance? Resolution of Pure Red Cell Aplasia With Daratumumab-Based Therapy.
Am J Med. 2024 Jul;137(7):589-591. doi: 10.1016/j.amjmed.2024.02.013. Epub 2024 Feb 22.
5
Restoration of erythropoiesis by rituximab in an adult patient with primary acquired pure red cell aplasia refractory to conventional treatment.利妥昔单抗使一名对传统治疗无效的成人原发性获得性纯红细胞再生障碍性贫血患者的红细胞生成得以恢复。
Br J Haematol. 2002 Mar;116(3):727-8. doi: 10.1046/j.1365-2141.2002.3317_3.x.
6
Refractory idiopathic pure red cell aplasia complicated by immune thrombocytopenia successfully treated with subcutaneous alemtuzumab.皮下注射阿仑单抗成功治疗难治性特发性纯红细胞再生障碍性贫血合并免疫性血小板减少症
Am J Hematol. 2008 Jul;83(7):603. doi: 10.1002/ajh.21155.
7
Pure Red Cell Aplasia following ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation: Resolution with Daratumumab Treatment.ABO 血型不合异基因造血干细胞移植后纯红细胞再生障碍：达妥木单抗治疗后缓解。
Acta Haematol. 2021;144(6):683-687. doi: 10.1159/000515257. Epub 2021 Apr 22.
8
Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation.达雷妥尤单抗治疗异基因移植后红细胞植入延迟。
N Engl J Med. 2018 Nov 8;379(19):1846-1850. doi: 10.1056/NEJMoa1807438.
9
Efficacy and safety of daratumumab in pure red cell aplasia after allogeneic transplantation: Dutch real-world data.达雷妥尤单抗在异基因移植后纯红细胞再生障碍性贫血中的疗效和安全性：荷兰真实世界数据
Blood Adv. 2024 Apr 9;8(7):1683-1686. doi: 10.1182/bloodadvances.2023011190.
10
Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H).使用抗CD52单克隆抗体阿仑单抗（Campath-1H）成功治疗与淋巴增殖性疾病相关的难治性纯红细胞再生障碍性贫血。
Br J Haematol. 2003 Oct;123(2):278-81. doi: 10.1046/j.1365-2141.2003.04609.x.

引用本文的文献

1
Anti-plasma cell therapy in patients with monoclonal gammopathy-associated refractory pure red cell aplasia: A report of three cases and literature review.单克隆丙种球蛋白病相关难治性纯红细胞再生障碍性贫血患者的抗浆细胞治疗：三例报告及文献综述
Ann Hematol. 2025 Aug 21. doi: 10.1007/s00277-025-06565-x.
2
Daratumumab for PRCA after HCT: study and practical considerations from the EBMT Transplant Complications Working Party.达雷妥尤单抗用于异基因造血干细胞移植后纯红细胞再生障碍性贫血：欧洲血液与骨髓移植协会移植并发症工作组的研究及实践考量
Blood Cancer J. 2025 Jun 4;15(1):106. doi: 10.1038/s41408-025-01315-8.
3
The role of daratumumab in complications post-allogeneic hematopoietic stem cell transplantation: a single-center prospective study on PRCA and AIHA.

本文引用的文献

1
Daratumumab may be the most effective treatment for post-engraftment pure red cell aplasia due to persistent anti-donor isohemagglutinins after major ABO-mismatched allogeneic transplantation.达雷妥尤单抗可能是治疗主要ABO血型不合的异基因移植后因持续性抗供者同种血凝素导致的植入后纯红细胞再生障碍性贫血的最有效疗法。
Bone Marrow Transplant. 2022 Feb;57(2):282-285. doi: 10.1038/s41409-021-01507-3. Epub 2021 Oct 28.
2
How I manage acquired pure red cell aplasia in adults.成人获得性纯红细胞再生障碍性贫血的治疗策略。
Blood. 2021 Apr 15;137(15):2001-2009. doi: 10.1182/blood.2021010898.
3
Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus.
达雷妥尤单抗在异基因造血干细胞移植后并发症中的作用：一项关于纯红细胞再生障碍性贫血和自身免疫性溶血性贫血的单中心前瞻性研究。
Bone Marrow Transplant. 2025 Mar;60(3):305-309. doi: 10.1038/s41409-024-02479-w. Epub 2024 Nov 20.
4
Seven-years post allogeneic hematopoietic stem cell transplantation pure red cell aplastic anemia cured with daratumumab: A case report and review of literature.异基因造血干细胞移植七年后，达雷妥尤单抗治愈纯红细胞再生障碍性贫血：一例报告并文献复习
World J Clin Cases. 2024 Aug 26;12(24):5604-5612. doi: 10.12998/wjcc.v12.i24.5604.
5
Refractory Pure Red Blood Cell Aplasia Secondary to Major ABO-Incompatible Allogeneic Stem Cell Transplantation Successfully Treated With Daratumumab.达雷妥尤单抗成功治疗主要 ABO 血型不相合异基因干细胞移植继发的难治性纯红细胞再生障碍性贫血
J Hematol. 2023 Dec;12(6):277-282. doi: 10.14740/jh1195. Epub 2023 Dec 9.
6
Daratumumab for autoimmune diseases: a systematic review.达雷妥尤单抗治疗自身免疫性疾病：系统评价。
RMD Open. 2023 Dec 14;9(4):e003604. doi: 10.1136/rmdopen-2023-003604.
达雷妥尤单抗治疗难治性系统性红斑狼疮的 CD38 靶点。
N Engl J Med. 2020 Sep 17;383(12):1149-1155. doi: 10.1056/NEJMoa2023325.
4
Successful treatment of refractory red cell aplasia after allogeneic hematopoietic cell transplantation with daratumumab.达雷妥尤单抗治疗异基因造血细胞移植后难治性红细胞再生障碍的疗效。
Eur J Haematol. 2020 Feb;104(2):145-147. doi: 10.1111/ejh.13343. Epub 2019 Nov 20.
5
Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients.治疗前CD38阳性调节性T细胞影响复发/难治性多发性骨髓瘤患者对达雷妥尤单抗的持久反应。
Haematologica. 2020 Jan;105(1):e37-e40. doi: 10.3324/haematol.2019.219683. Epub 2019 Apr 19.
6
Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation.达雷妥尤单抗治疗异基因移植后红细胞植入延迟。
N Engl J Med. 2018 Nov 8;379(19):1846-1850. doi: 10.1056/NEJMoa1807438.
7
Rational management approach to pure red cell aplasia.纯红细胞再生障碍性贫血的合理治疗方法。
Haematologica. 2018 Feb;103(2):221-230. doi: 10.3324/haematol.2017.175810. Epub 2017 Dec 7.
8
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.达雷妥尤单抗可清除CD38+免疫调节细胞，促进T细胞扩增，并使多发性骨髓瘤中的T细胞库发生偏移。
Blood. 2016 Jul 21;128(3):384-94. doi: 10.1182/blood-2015-12-687749. Epub 2016 May 24.
9
Monoclonal gammopathy-associated pure red cell aplasia.单克隆丙种球蛋白病相关的纯红细胞再生障碍性贫血。
Br J Haematol. 2016 Jun;173(6):876-83. doi: 10.1111/bjh.14012. Epub 2016 Mar 21.